OXYTROL: HCP - OXYTROL Highlights

U.S. Prescribing Information >> | OXYTROL Highlights >> | OXYTROL Clinical Results >> | Reimbursement Information >>
Frequently Asked Questions >> | Instructions for Your Patients >>

OXYTROL Highlights
Give them relief that lasts all day and all night [1]

Unique transdermal technology of OXYTROL provides long-lasting, consistent delivery of oxybutynin for up to 4 days [1]

Achieves steady-state plasma concentrations within 1 week [1]
Minimizes peak-to-trough fluctuations [1]
Allows for convenient twice-weekly dosing [1]

Please see full prescribing information for OXYTROL

Oxytrol Highlight References:
* Plasma oxybutynin concentrations measured during a multiple-dose, randomized, crossover study in 13 healthy volunteers.


	[1] OXYTROL® Prescribing Information. February 2003. [2] Dmochowski RR, Davila GW, Zinner NR, et al, for the Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168:580-586. [3] Data on file, Watson Pharma, Inc. [4] Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237-242. [5] Appel RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696-702. [6] Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW.Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res. 2001;18:1029-1034. [7] OXYTROL® Patient Prescribing Information.